REG - Indivior PLC - Publication of Notice of General Meeting

IndiviorAnnouncement

03/05/2024 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240503:nRSC2324Na&default-theme=true

RNS Number : 2324N  Indivior PLC  03 May 2024

May 3, 2024

Indivior PLC (the 'Company')

Publication of Circular and Notice of General Meeting

On April 25, 2024, the Board of Directors of the Company confirmed its
intention, following extensive consultation with shareholders, to seek
shareholder approval in May 2024 to effect a primary listing in the U.S.,
while maintaining a secondary listing in the U.K.. In order to effect a
primary listing in the U.S., shareholder approval is being sought to transfer
the Company's listing category on the Official List of the U.K. Financial
Conduct Authority ("FCA") from a Premium Listing (commercial company) to a
Standard Listing (shares) (the "Proposed Transfer").

 

Further to that announcement, the Company has today posted or made available
to shareholders a circular (the "Circular") incorporating a notice of general
meeting (the "General Meeting") regarding the Proposed Transfer.

Copies of the following documents have been submitted to the FCA and will
shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) :

- Circular incorporating the notice of General Meeting; and

- Form of Proxy for the General Meeting.

The Circular incorporating the notice of General Meeting can also be viewed on
the Company's website
at www.indivior.com/en/investors/shareholder-information
(http://www.indivior.com/en/investors/shareholder-information)  and will be
available for inspection at the place of the General Meeting for at least 15
minutes before and during the General Meeting.

The General Meeting will be held on Thursday, May 23, 2024, at 12.00 p.m.
(U.K. time) at the offices of Freshfields Bruckhaus Deringer LLP, 100
Bishopsgate, London EC2P 2SR.

 

The expected timetable for the General Meeting and the Proposed Transfer is
set out below. All times shown in this timetable are U.K. time.

 

 Event                                                                             Expected time/date
 Record date for DTC beneficial owners to be eligible to vote                      Friday, May 10, 2024
 Latest time and date for receipt of Forms of Direction                            12.00p.m. on

(U.K. CSN holders)
 Friday, May 17, 2024
 Record date for CSN holders to be eligible to vote                                6.00p.m. on

Friday, May 17, 2024
 Record date for U.K. Depositary Interest holders to be eligible to vote           6.00p.m. on

 Friday, May 17, 2024
 Latest time and date for receipt of Forms of Instruction                          12.00p.m. on

(U.K. Depositary Interest holders)
 Monday, May 20, 2024
 Latest time and date for receipt of Forms of Proxy                                12.00p.m. on

(direct shareholders)                                                            Tuesday, May 21, 2024
 Record date for direct shareholders to attend and vote                            12.00p.m. on

at the General Meeting
 Tuesday, May 21, 2024
 General Meeting                                                                   12.00p.m. on

 Thursday, May 23, 2024
 Proposed Transfer becomes effective and trading of Indivior Shares commences      8.00a.m. on
 as a Standard Listing company
Thursday, June 27, 2024

 

All dates are based on Indivior's current expectations and may be subject to
change. If any of the times or dates change, Indivior will give notice of the
change by issuing an announcement through a Regulatory Information Service.

Capitalised terms used but not otherwise defined in this announcement have the
same meaning given to them in the Circular.

 

Key Contacts:

Jason Thompson

VP, Investor Relations

+1 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

+1 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

Kathryn Hudson

Company Secretary

+44 (0)1753 423940 or kathryn.hudson@indivior.com
(mailto:kathryn.hudson@indivior.com)

 

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs over 1,100 individuals
globally and its portfolio of products is available in 37 countries worldwide.
Visit www.indivior.com
(https://indiviorplc-my.sharepoint.com/personal/timothy_owens_indivior_com/Documents/Desktop/a.%20Quarters/j.%20Q124/Calendar%20invite/www.indivior.com)
 to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/ company/indivior
(https://indiviorplc-my.sharepoint.com/personal/timothy_owens_indivior_com/Documents/Desktop/a.%20Quarters/j.%20Q124/Calendar%20invite/www.linkedin.com/%20company/indivior)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGQKNBKNBKDCPK